194534-83-3Relevant academic research and scientific papers
Nitrilases catalyze key step to conformationally constrained GABA analogous γ-amino acids in high optical purity
Winkler, Margit,Knall, Astrid C.,Kulterer, Martin R.,Klempier, Norbert
, p. 7423 - 7426 (2007)
(Chemical Equation Presented) Five- and six-membered carbocyclic γ-amino acids were prepared in high enantiomeric purity by nitrilase-mediated transformation of hitherto unreported γ-amino nitriles. The nitrilases investigated reveal a strong enantioprefe
Glutaminase inhibitors as well as compositions and applications thereof
-
, (2018/01/09)
The invention provides a series of heterocyclic compounds expressed in a formula I. The compound comprises glutaminase inhibition activity, and can be used for treating diseases and symptoms related to dysfunction of glutaminase or raising activity of glutaminase.
PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE
-
, (2016/02/29)
Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.
2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
-
, (2015/12/07)
In its many embodiments, the present invention provides certain iminothiazine dioxide compounds, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein each of the variables shown in the formula are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer's disease, are also disclosed.
FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES
-
, (2013/03/26)
The invention provides novel compounds of formula (I) having the general formula (I) wherein R1, V, W, X, Y and Z are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.
